SEC Tracker
Get the app

Allarity Therapeutics ALLR

Allarity Therapeutics FY 2023: net loss $11.9M; diluted EPS −$10.26

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Allarity Therapeutics reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$11.9MAgainst −$16.1M in FY 202210-K income statement, on EDGAR
  2. Diluted EPS−$10.26Against −$2.21 in FY 202210-K income statement, on EDGAR
  3. Cash and cash equivalents$166K−92% from $2.0M in FY 202210-K balance sheet, on EDGAR
  4. Cash from operations−$12.7MAgainst −$16.8M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Allarity Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
  2. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  3. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  4. Pluri PLUR public float $15M, Dec 31, 2025
  5. Edesa Biotech EDSA public float $14M, Mar 31, 2025, over 18 months old